2015
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults
Ishida JH, Burgess T, Derby MA, Brown PA, Maia M, Deng R, Emu B, Feierbach B, Fouts AE, Liao XC, Tavel JA. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. Antimicrobial Agents And Chemotherapy 2015, 59: 4919-4929. PMID: 26055360, PMCID: PMC4505204, DOI: 10.1128/aac.00523-15.Peer-Reviewed Original ResearchConceptsHealthy adultsPlacebo groupAdverse eventsMonoclonal antibodiesDose-proportional pharmacokineticsMost adverse eventsDose-escalation studyMonoclonal antibody therapyProportion of subjectsHuman monoclonal antibodyOverall pharmacokinetic profileLife-threatening diseasePhase 1Transplant recipientsCytomegalovirus infectionAntibody therapyImmunogenicity profileMultiple dosesAntibody responseImmunocompromised individualsPharmacokinetic profileSusceptible populationAdultsHost targetsTherapy
2011
A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers
Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, Norris PJ, Busch MP, Martin JN, Brooks C, McCune JM, Deeks SG. A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers. PLOS ONE 2011, 6: e15924. PMID: 21305005, PMCID: PMC3031543, DOI: 10.1371/journal.pone.0015924.Peer-Reviewed Original ResearchConceptsT cell activation levelsT cell responsesHigh T-cell activation levelsHIV-specific T-cell responsesRegulatory cell responsesHIV controllersImmune activationCell responsesCMV-specific T cellsT regulatory (Treg) cell responsesTreatment-mediated viral suppressionEffective adaptive immune responseCMV-specific CD4Generalized immune activationHIV-specific CD4Lower Treg frequenciesNon-AIDS morbiditiesT cell frequenciesT cell lossT-cell depletionT cell dysfunctionAbsence of therapyActivation levelsAdaptive immune responsesDevelopment of vaccines
2007
Loss of T cell responses following long-term cryopreservation
Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, Tan QX, Custer B, Harris JM, Jacobson MA, McCune JM, Martin JN, Hecht FM, Deeks SG, Norris PJ. Loss of T cell responses following long-term cryopreservation. Journal Of Immunological Methods 2007, 326: 93-115. PMID: 17707394, PMCID: PMC2065759, DOI: 10.1016/j.jim.2007.07.012.Peer-Reviewed Original ResearchConceptsT cell IFN-gamma responsesT cell responsesHuman immunodeficiency virusIFN-gamma responsesPeripheral blood mononuclear cellsCell responsesLong-term cryopreservationPeptide poolsHIV-negative individualsBlood mononuclear cellsLoss of responseT cell apoptosisPhenotypic marker expressionDecrement of responseOvernight restingEffector cellsImmunodeficiency virusExogenous antigensMononuclear cellsShort-term cryopreservationHIV peptidesFuture vaccinesImpact of cryopreservationPathogenesis studiesMarker expression